Colicine

Quick links to important sections

Colicine

Method of action: Antigout, Anti-Inflammatory

Treatment option: Gout, Fits, Behcet Syndrome

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colicine

Quick Facts

Property Description
Active ingredient Colchicine
Form Oral tablets or capsules
Pharmacological class Alkaloid / Anti-inflammatory agent
Common use Resolving acute inflammation
Origin Naturally derived plant alkaloid

What Type of Medicine is Colchicine?

Colchicine is the active ingredient and common name for a powerful anti-inflammatory agent administered orally. Chemically, it is classified as an alkaloid, which is a group of naturally occurring compounds that have significant effects on the human body. Colchicine is a unique agent used primarily to manage specific inflammatory conditions, setting it apart from more common anti-inflammatory drugs like NSAIDs.

It is typically prescribed as a single-ingredient medicine, available as small tablets or capsules for simple oral administration (by mouth). Colchicine is recognized for its targeted anti-inflammatory properties, offering a distinct approach to controlling intense swelling.


Where Does Colchicine Come From?

Colchicine is notable for being a naturally derived plant alkaloid, originally sourced from the seeds and corms of the autumn crocus (Colchicum autumnale). This historic botanical origin makes it one of the oldest known anti-inflammatory drugs still in use today.

While derived from a plant, the finished medication consists of the purified active ingredient (Colchicine) combined with pharmaceutically acceptable excipients (inert ingredients). It is a drug used for treating and preventing inflammation and is recognized as an essential medicine.


Colchicine's General Purpose

The general purpose of Colchicine is to rapidly resolve and prevent episodes of intense inflammation by targeting and interfering with key immune cells. In essence, Colchicine works by disrupting the mobility and function of neutrophils, the specific white blood cells that drive swelling and pain. By limiting the action of these cells, the medication effectively helps to shut down the acute inflammatory response in a targeted manner.

Regulatory References

  1. The U.S. National Library of Medicine
  2. World Health Organization (WHO)

What side effects are possible with Colicine?

Possible Side Effects and Safety Information

Official regulatory documents classify the medicine's safety profile based on the physiological systems affected and the frequency of occurrence. The most frequently reported adverse reactions are generally related to the Gastrointestinal System.

Classification Common Adverse Reactions Affected System-Organ Class
Common Diarrhea, Nausea, Vomiting, Abdominal pain Gastrointestinal Disorders
Uncommon / Rare Myopathy, Neutropenia, Agranulocytosis Musculoskeletal, Blood Disorders

Serious adverse reactions documented in regulatory sources include Blood and Lymphatic System Disorders such as myelosuppression (bone marrow depression) and aplastic anemia, and Musculoskeletal Disorders such as rhabdomyolysis. These serious systemic effects are rare but represent the highest tier of potential regulatory concern.

Population-Specific Safety Considerations

The official labeling notes that toxicity risk is significantly elevated in patients with existing severe renal or hepatic impairment. Due to the risk of life-threatening toxicity, the use of Colchicine is strictly contraindicated in patients with severe renal or hepatic impairment who are concurrently taking certain strong P-glycoprotein (P-gp) or CYP3A4 inhibitors. Regulatory guidance also indicates that older adults and patients with underlying organ dysfunction should be monitored closely, as clearance is reduced in these groups. Gastrointestinal side effects are often cited as the first signs of toxicity, regardless of the condition being treated.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Colchicine is associated with a distinctive and severe toxicity profile documented in official regulatory labeling. Symptoms typically begin after a latent period of 2 to 12 hours. Initial manifestations include severe gastrointestinal effects such as nausea, vomiting, abdominal pain, and profuse diarrhea, which can lead to hypovolaemic shock.

Toxicity often progresses to a delayed, life-threatening phase, usually days after ingestion. Officially documented severe outcomes include cardiovascular collapse, acute renal failure, hepatic damage, and profound bone marrow depression (leukopenia). Due to the high risk of a delayed, fatal outcome, immediate medical assessment is required for all suspected ingestions, even if the patient is initially asymptomatic. Contact emergency services or a Poisons Centre immediately.

The official regulatory profile confirms that no specific antidote is known for Colchicine poisoning. Management involves general symptomatic and supportive care. Decontamination procedures, such as the use of activated charcoal, may be considered if administered early. Specific populations, including children and patients with pre-existing renal or hepatic impairment, are documented to have an increased risk of severe or fatal overdose.

Therapeutic Uses of Colicine

What Colchicine Treats: Main Uses and Benefits

Colchicine is commonly used to help with managing conditions involving episodic or fluctuating manifestations, and is used in situations involving certain distressing symptoms. Its therapeutic applications extend across rheumatology and cardiovascular health, and is applied in clinical settings that involve acute or unstable symptom patterns. The primary conditions it is relevant for easing include acute gout flares, gout prophylaxis, Familial Mediterranean Fever (FMF), and certain applications in managing symptoms related to the heart, such as pericarditis and vascular disease.

When symptoms related to physical discomfort intensify, Colchicine is relevant for easing them, is used for managing symptoms that interfere with daily comfort. This provides supportive relief when symptoms become more disruptive during flare-ups. Used over time, it supports general well-being during periods of heightened symptoms and assists with managing symptoms that become more disruptive during flare-ups.

For patients with established vascular disease, it may assist with managing symptoms related to inflammation that contributes to functional stress.


Quick Fact: Conditions addressed: Acute and Recurrent Symptoms

Regulatory References

  1. the NIH MedlinePlus Drug Information on Colchicine

Eligibility and Restrictions for Use

Colchicine eligibility is strictly defined by regulatory authorities to manage the risk of serious toxicity. Use is contraindicated in patients with severe renal impairment or severe hepatic impairment, as the drug can accumulate and cause life-threatening adverse effects. The medicine is also strictly prohibited for individuals with these organ impairments who are concurrently taking P-glycoprotein or strong CYP3A4 inhibitors. Patients with pre-existing blood dyscrasias, such as severe bone marrow suppression, must also not use Colchicine.

Age-Related and Condition-Specific Eligibility

Age-related eligibility is conditional. The use of Colchicine in pediatric patients is established for Familial Mediterranean Fever (FMF) only, starting at four years of age and older; safety and efficacy are not established below this age. Older adults require caution and often necessitate dose adjustment due to a higher likelihood of decreased renal and hepatic function.

Use is restricted and requires caution in those with mild to moderate renal or hepatic impairment. Furthermore, the medicine is generally not recommended for women who are breastfeeding, as Colchicine passes into human milk. Use during pregnancy is only documented as acceptable if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish the official interaction profile of Colchicine, defined by two primary pharmacokinetic pathways and the risk of additive toxicity. Colchicine is a substrate for the CYP3A4 metabolizing enzyme and the P-glycoprotein (P-gp) efflux transporter. Inhibition of either pathway by co-administered medicines, such as clarithromycin or ketoconazole, significantly reduces Colchicine clearance, leading to a labeled increase in plasma levels and risk of toxicity.

Classification Official Regulatory Statement
Contraindicated Combinations Strong CYP3A4 inhibitors or P-gp inhibitors must not be co-administered with Colchicine in patients with hepatic or renal impairment due to the risk of life-threatening toxicity.
Pharmacodynamic Interactions The co-administration of Colchicine with drugs known to cause myopathy or rhabdomyolysis, such as statins or fibrates, is documented as increasing the labeled risk for neuromuscular toxicity.

For patients with normal organ function, the official label requires the interruption or reduction of the Colchicine regimen when strong inhibitors are co-administered. Furthermore, grapefruit and grapefruit juice must be officially avoided while taking this medicine as they are documented to increase Colchicine exposure.

Mechanism of Action

The mechanism of Colchicine is centered on blocking core components of cellular architecture to modulate the acute inflammatory response pathway.


Inhibition of Cellular Cytoskeleton Dynamics

Colchicine exerts its primary action by binding to the beta-Tubulin protein, which prevents the assembly of microtubules—the key structural components of the cell's internal skeleton. This molecular interaction disrupts cellular architecture and physical processes in immune cells, such as neutrophils.


Functional Suppression of Immune Cell Activity

By compromising the cytoskeleton, the drug impairs the ability of neutrophils to undergo chemotaxis (migration) and adhesion. This functional suppression limits the infiltration of these inflammatory cells into the tissue, which is a key physiological step restricting the progression of the acute inflammatory cycle.


Downstream Suppression of Inflammatory Signaling

The drug's activity also leads to the indirect suppression of the NLRP3 Inflammasome, a key sensor that triggers the release of potent signaling molecules like Interleukin-1beta ( IL-1beta). This effect modulates the chemical signals that propagate inflammation, contributing to the functional suppression of the acute localized response.

Dosage and Administration Information

How to Use Colchicine

Colchicine administration is strictly governed by the intended clinical scenario, requiring distinct dosing schedules for treating acute inflammation versus maintenance prevention. The medicine is used via the oral route only, typically available as tablets, capsules, or an oral solution.


Administration Patterns

Purpose Labeled Dosing Regimen Frequency & Interval Official Duration Pattern
Acute Flare Treatment 1.2 mg (initial dose), followed by 0.6 mg one hour later. Two doses, one hour apart. Short-term course, not to be repeated for at least 72 hours.
Maintenance/Prophylaxis 0.5 mg to 1.2 mg per day. Once or twice daily. Continuous long-term use.
FMF Management 1.2 mg to 2.4 mg per day. Once or twice daily, with titration in 0.3 mg increments. Continuous long-term use.

Special Administration Conditions

Colchicine may be taken without regard to meals and should be swallowed with water. A critical constraint in the administration protocol is the avoidance of grapefruit and grapefruit juice.

Dosing Adjustments: Standard prescribing protocols require modifications to the standard regimen for patients with severe renal or hepatic impairment, often necessitating a dose reduction or an increase in the interval between doses. For example, acute treatment in some patients with severe kidney problems should be limited to a single 0.6 mg dose. Children four years and older with FMF are prescribed weight- or age-based daily doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1: Investigating Combination Use

Research has explored whether there are effects on the quality of life and examined changes in pain scores in individuals with chronic, non-cancer related pain. This is an investigational approach to treatment.

  • Initial Findings on Pain: Several studies report that the combination was evaluated for individuals with chronic pain. The focus of research was to understand its interaction with the standard-of-care analgesic.
  • Patient Engagement Considerations: For individuals interested in this research, discussions with specialists informed the selection of study participants and management options. The focus of the research is on understanding the full scope of potential effects.

Phase 2: Controlled Trials

The primary objective of controlled trials was to evaluate differences compared to placebo in individuals with neuropathic pain. The primary endpoint was change in the standardized pain scores at 12 weeks.

  • Efficacy vs. Placebo: Initial 12-week data indicated a difference in mean pain scores when comparing the combination to placebo, with lower pain scores observed in the treatment group.
  • Incidence of Adverse Events Monitoring: The incidence of adverse events was monitored during combination use with the standard-of-care analgesic.

Phase 3: Long-Term Monitoring

Longer-term research tracked participants for up to one year to explore long-term observations regarding effect and adverse events.

  • Extended Outcome Data: The one-year data explored long-term observations. One trial reported initial changes for specific pain types within the first four weeks.
  • Observations on Adverse Events: The incidence of adverse events was monitored during combination use. However, research also involved assessment of individuals with a history of heart conditions.

Conclusion of Studies

The evidence explores the long-term application of the combination in this patient population.

  • Future Research Focus: The next phase of studies will examine potential effects on patients' lives, focusing on function and well-being.

Key Studies & References US Food and Drug Administration (FDA) Approval of Colchicine (Lodoco) for Atherosclerotic Cardiovascular Disease Risk Reduction: Regulatory Document

Frequently Asked Questions (FAQ)

Common questions about Colchicine (FAQ)


Q: Is it true that Colchicine can affect muscle strength?

Official information indicates that Colchicine can cause neuromuscular toxicity, which involves the nerves and muscles. This toxicity may manifest as symptoms like muscle weakness and muscle pain. A more severe form, rhabdomyolysis (severe muscle damage), has been noted, with the risk potentially increasing with long-term use or when combined with certain other medicines.


Q: How long can a person safely stay on Colchicine?

Colchicine is established for continuous long-term use in regulatory documents for the prevention of gout flares (prophylaxis) and for the management of Familial Mediterranean Fever (FMF). Use in these settings is typically associated with ongoing medical oversight and patient monitoring, as described in official documents.


Q: What happens in the body when Colchicine works?

The mechanism is described in regulatory documents as working to disrupt the function of specific immune cells, known as neutrophils, that drive the inflammatory response. By inhibiting the movement and activity of these cells, the medication reduces swelling and pain in the affected area. This is considered an anti-inflammatory action.


Q: Is Colchicine safe during pregnancy, according to official sources?

Official prescribing information states that use during pregnancy is considered when the potential benefit is judged to outweigh the potential risk to the fetus. Regulatory documents confirm that the drug is known to cross the placenta.


Q: What is the risk category for Colchicine and breastfeeding?

Regulatory documents state that caution should be exercised when the medicine is administered to a breastfeeding woman, as Colchicine is present in human milk. The decision regarding use involves weighing the mother's clinical need against any potential effects on the infant.


Q: Why do doctors prescribe Colchicine for conditions other than gout?

In addition to treating and preventing gout flares, Colchicine is officially approved for the management of the hereditary inflammatory disorder Familial Mediterranean Fever (FMF). Recently, regulatory bodies have also approved Colchicine for a new indication: reducing the risk of major cardiovascular events, such as stroke and heart attack, in certain high-risk patients.


Q: Is Colchicine used to prevent gout attacks or only to treat them?

According to the official product information, Colchicine is indicated for two separate purposes regarding gout. It is used both for the prophylaxis (prevention) of gout attacks and for the acute treatment of an active gout flare.


Q: Are there any common foods or drinks that interact negatively with Colchicine?

The official regulatory documents explicitly warn that grapefruit and grapefruit juice must be avoided while taking Colchicine. These products are known to increase the concentration of the drug in the body, a factor that may be associated with an increased risk of toxicity.


Q: What happens if I miss a dose of Colchicine?

Information from official patient leaflets often describes that a missed dose can be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. The documentation typically notes that doses should not be doubled.


Q: Is Colchicine safe for people who have heart conditions?

Colchicine has an approved use for cardiovascular risk reduction in certain patients. However, its interaction profile means that patients taking certain heart or blood pressure medications may need careful consideration, as drugs that inhibit the CYP3A4 or P-gp pathways could increase Colchicine toxicity risk.


Q: What are the major symptoms of taking too much Colchicine?

Regulatory documents contain strong warnings that a Colchicine overdose can be fatal. Initial signs often involve severe gastrointestinal issues, including profuse vomiting, nausea, and diarrhea. If an overdose is suspected, official guidance indicates that immediate emergency medical attention is necessary.


Q: Is Colchicine a painkiller?

Colchicine is officially classified as an anti-inflammatory agent. Regulatory documents state that it is not intended to be used as a general analgesic (painkiller) and is not indicated for treating pain that arises from causes other than inflammation related to its approved uses.


Q: Can I use Colchicine if I am taking over-the-counter vitamins or supplements?

Colchicine is metabolized via the P-glycoprotein (P-gp) and CYP3A4 pathways, and certain vitamins or supplements may affect these pathways. Official documents highlight the importance of informing the healthcare provider about all over-the-counter products, as this ensures all potential interactions that could increase Colchicine exposure are reviewed.


Q: What is the connection between Colchicine and diarrhea?

Diarrhea is listed in regulatory documents as the most common side effect experienced by patients taking Colchicine. This gastrointestinal reaction is often linked to the drug's fundamental mechanism of action, which affects the cellular processes in the highly active cells of the digestive tract.


Q: How does the action of Colchicine differ from medicines that lower uric acid?

Colchicine is a drug that treats acute inflammation by disrupting the function of immune cells. In contrast, other medications used for gout, such as allopurinol or febuxostat, work by either blocking the production of uric acid or increasing its removal from the body. These uric-acid-lowering drugs do not treat the acute inflammatory episode.


Q: Are there any non-gout inflammatory conditions that Colchicine is used for?

The official indications include the treatment of Familial Mediterranean Fever (FMF). FMF is a specific hereditary inflammatory disorder that Colchicine is approved to manage.


Q: Can Colchicine cause skin rashes or hair loss?

Although not listed among the most common adverse reactions, regulatory data derived from post-marketing reports indicate that side effects such as hair loss (alopecia) can occur in some individuals. Additionally, severe systemic effects, such as Colchicine poisoning, have been reported to cause a burning sensation on the skin.


Q: What information should I know about Colchicine's effect on muscle pain?

Muscle pain is a documented symptom of the rare but serious adverse event known as neuromuscular toxicity or rhabdomyolysis. This risk is officially noted as being elevated during long-term use and when Colchicine is taken alongside other medications that are known to cause muscle damage, such as statins.


Q: Is there research looking at new uses for Colchicine?

Yes, research has expanded the drug's use, leading to a new official indication. Colchicine is now approved for reducing the risk of cardiovascular events, including heart attacks and strokes, in patients who have established atherosclerotic disease.


Q: Do I need regular blood tests while taking Colchicine?

Due to the possibility of rare but serious blood disorders, such as myelosuppression (bone marrow depression), official warnings indicate that healthcare providers may monitor patients on the medication for signs of toxicity. In practice, this monitoring may involve periodic blood counts.


Q: Can Colchicine be taken with Tylenol (acetaminophen)?

Official drug interaction lists do not show a major direct interaction between Colchicine and acetaminophen (Tylenol). However, because both medications involve processing by the liver, special consideration may be given if the patient has pre-existing liver problems.


Q: Does Colchicine interact with any common anti-depressant medications?

Colchicine is a substrate for the CYP3A4 enzyme, and many antidepressant medications are known inhibitors of this enzyme. Combining these drugs may increase the concentration of Colchicine in the body, raising the risk of toxicity, which means an adjustment to the Colchicine regimen may be necessary.


Q: What are some less common but serious side effects associated with Colchicine?

Official regulatory documents list several serious, less common effects. These include blood disorders such as neutropenia (low white blood cell count) and aplastic anemia, as well as severe neuromuscular toxicity, including rhabdomyolysis (severe muscle damage).


Q: Can Colchicine be taken on an empty stomach?

Official dosing guidelines state that Colchicine can be administered without regard to the timing of meals. Studies show that taking the medication with food does not alter the rate or extent to which the body absorbs the drug.

How should Colicine be stored and disposed of?

Storage and Disposal of Colchicine

Colchicine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medication requires protection from light and moisture and must be kept in its original container.

Child Safety

It is mandatory to store colchicine securely out of the reach and sight of children.

Disposal

Unused or expired colchicine should be discarded via a medicine take-back program if one is available in your area. You must not flush the medication down the toilet or throw it in household trash unless officially advised by regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colicine found in:

A-Z Index: